Loading
A phase 2 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC is a phase 2 interventional study registered as NCT04919811 by Nuvation Bio Inc., with 217 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-06-11. Interventions recorded: Taletrectinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Nuvation Bio, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.